Study for Patients With Non Small Cell Lung Cancer (NSCLC)

Randomized Phase II Study to Determine the Efficacy of a Three Weekly vs. Weekly Therapy With Paclitaxel Plus Carboplatin vs. Paclitaxel Plus Vinorelbine for Patients With Non Small Cell Lung Cancer According to UICC Stage IIIB and IV

This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.

Randomized Phase II design, multicenter study, to assess the efficacy and safety of combined chemotherapy with Paclitaxel and Carboplatin versus a platinum free chemotherapy with Paclitaxel and Vinorelbine, within the combination therapies there are two different dosing intervals, which will be assessed as well (4 Arm study).

Inclusion Criteria:

• Chemotherapy naive patients with histologically confirmed NSCLC stage III and IV

Exclusion Criteria:

• New York Heart Association (NYHA) III or IV
• Brain metastases
• Neurotoxicity Grade 2 or greater